| 13/11/24 | 16:00:00 | 13 Nov 2024 | | Director/PDMR Shareholding |
| 12/11/24 | 07:10:04 | 12 Nov 2024 | | AstraZeneca invests $3.5 billion in US |
| 12/11/24 | 07:05:00 | 12 Nov 2024 | | KOMET Phase III trial met primary endpoint |
| 12/11/24 | 07:00:07 | 12 Nov 2024 | | 9M and Q3 2024 Results |
| 12/11/24 | 07:00:06 | 12 Nov 2024 | | Dato-DXd new BLA submitted, NSQ BLA withdrawn |
| 08/11/24 | 07:00:08 | 8 Nov 2024 | | Tezspire nasal polyps trial met primary endpoints |
| 05/11/24 | 16:49:43 | 5 Nov 2024 | | AZN share price movement |
| 01/11/24 | 15:00:00 | 1 Nov 2024 | | Total Voting Rights |
| 30/10/24 | 13:00:00 | 30 Oct 2024 | | AZN China President under investigation |
| 21/10/24 | 07:00:04 | 21 Oct 2024 | | Wainzua recommended for approval in the EU |
| 07/10/24 | 09:30:00 | 7 Oct 2024 | | AstraZeneca licenses lipid lowering Lp(a) asset |
| 01/10/24 | 15:00:00 | 1 Oct 2024 | | Total Voting Rights |
| 26/09/24 | 07:00:13 | 26 Sept 2024 | | Tagrisso US approval in unresectable lung cancer |
| 23/09/24 | 07:05:01 | 23 Sept 2024 | | Fasenra recommended for EU approval in EGPA |
| 23/09/24 | 07:00:07 | 23 Sept 2024 | | Final OS results reported for TROPION-Breast01 |
| 20/09/24 | 18:00:00 | 20 Sept 2024 | | FluMist approved for self-administration in US |
| 18/09/24 | 07:00:07 | 18 Sept 2024 | | Fasenra EGPA US FDA approval |
| 13/09/24 | 15:15:00 | 13 Sept 2024 | | Director/PDMR Shareholding |
| 02/09/24 | 15:00:00 | 2 Sept 2024 | | Total Voting Rights |
| 16/08/24 | 07:00:06 | 16 Aug 2024 | | Imfinzi approved in US for resectable lung cancer |
| 01/08/24 | 15:00:01 | 1 Aug 2024 | | Total Voting Rights |
| 30/07/24 | 07:00:07 | 30 Jul 2024 | | AstraZeneca prices a €1.4bn bond offering |
| 29/07/24 | 08:41:44 | 29 Jul 2024 | | Stabilisation Notice - ASTRAZENECA |
| 29/07/24 | 07:00:06 | 29 Jul 2024 | | Calquence fixed-duration combo improved 1L CLL PFS |
| 26/07/24 | 07:00:08 | 26 Jul 2024 | | ODAC reviewed Imfinzi in resectable lung cancer |
| 25/07/24 | 07:00:10 | 25 Jul 2024 | | Half-year Report |
| 15/07/24 | 07:00:03 | 15 Jul 2024 | | Acquisition of Amolyt Pharma completed |
| 01/07/24 | 15:00:01 | 1 Jul 2024 | | Total Voting Rights |
| 01/07/24 | 07:00:03 | 1 Jul 2024 | | Lynparza & Imfinzi positive CHMP in endometrial |
| 25/06/24 | 07:05:00 | 25 Jun 2024 | | Update on Imfinzi ADJUVANT BR.31 trial |
| 25/06/24 | 07:00:08 | 25 Jun 2024 | | Imfinzi improved EFS and OS in bladder cancer |
| 18/06/24 | 07:00:09 | 18 Jun 2024 | | Update on CAPItello-290 Phase III trial |
| 17/06/24 | 07:00:09 | 17 Jun 2024 | | Imfinzi approved in the US for endometrial cancer |
| 12/06/24 | 15:00:00 | 12 Jun 2024 | | Director/PDMR Shareholding |
| 05/06/24 | 07:00:06 | 5 Jun 2024 | | Acquisition of Fusion completed |
| 03/06/24 | 15:05:01 | 3 Jun 2024 | | Block listing Interim Review |
| 03/06/24 | 15:00:00 | 3 Jun 2024 | | Total Voting Rights |
| 03/06/24 | 07:00:10 | 3 Jun 2024 | | Tagrisso plus chemo recommended for approval in EU |
| 28/05/24 | 07:00:16 | 28 May 2024 | | Dato-DXd improved OS in nonsquamous lung cancer |
| 21/05/24 | 07:00:09 | 21 May 2024 | | AstraZeneca to deliver $80bn revenue by 2030 |
| 20/05/24 | 07:00:07 | 20 May 2024 | | AstraZeneca to manufacture ADCs in Singapore |
| 16/05/24 | 07:00:07 | 16 May 2024 | | SUPERNOVA Trial Met COVID-19 prevention endpoint |
| 15/05/24 | 15:00:00 | 15 May 2024 | | Director/PDMR Shareholding |
| 07/05/24 | 07:00:14 | 7 May 2024 | | AstraZeneca completes Cellectis equity investment |
| 02/05/24 | 07:00:10 | 2 May 2024 | | Calquence combination improved PFS in 1L MCL |
| 01/05/24 | 15:00:01 | 1 May 2024 | | Total Voting Rights |
| 29/04/24 | 07:05:00 | 29 Apr 2024 | | Truqap recommended for EU breast cancer approval |
| 29/04/24 | 07:00:09 | 29 Apr 2024 | | Enhertu improved PFS in HER2-low and ultralow |
| 25/04/24 | 07:00:11 | 25 Apr 2024 | | 1st Quarter Results |
| 11/04/24 | 17:30:00 | 11 Apr 2024 | | Result of AGM |
